Characteristic	Mortality	Morbidity	Adverse events	Notes
Derosa 2004 I1: rosiglitazone 4 mg + glimepiride 4 mg C1: pioglitazone 15 mg + glimepiride 4 mg	not investigated	not investigated	see table 'Adverse events'	./.
Derosa 2006a I1: rosiglitazone 4 mg + metformin 3 g C1: pioglitazone 15 mg + metformin 3 g	not investigated	not investigated	see table 'Adverse events'	./.
Derosa 2006b I1: rosiglitazone 4 mg + metformin 1.5 g C1: glimepiride 2 mg + metformin 1.5 g	not investigated	not investigated	see table 'Adverse events'	./.
Garber 2006 I1: rosiglitazone 4 mg + metformin 2 g C1: glibenclamide 5 mg + metformin 1 g	not investigated	not investigated	see table 'Adverse events'	./.
Goldberg 2005 I1: rosiglitazone 8 mg C1: pioglitazone 45 mg	not investigated	not investigated	see table 'Adverse events'	./.
Hällsten 2002 I1: rosiglitazone 8 mg I2: metformin 2 g C1: placebo	not investigated	not investigated	see table 'Adverse events'	./.
Hanefeld 2007 I1: rosiglitazone (2 mg bid) + placebo I2: rosiglitazone (4 mg bid) + placebo C1: glibenclamide up to 15 mg + placebo	not investigated	not investigated	see table 'Adverse events'	./.
Jung 2005 I1: rosiglitazone 4 mg + glimepiride 4 mg C1: metformin 1 g + glimepiride 4 mg	not investigated	not investigated	see table 'Adverse events'	./.
Kahn 2006 I1: rosiglitazone max. 8 mg C1: metformin max. 2 g C2: glyburide max. 15 mg	death rates reported but not part of the efficacy outcomes, as defined in the publication of the study design (Diabetes Care 2002): deaths from any cause [no]: I1: 34 C1: 31 C2: 31	morbidity rates reported but not part of the efficacy outcomes, as defined in the publication of the study design (Diabetes Care 2002): cardiovascular disease [no (%)]: serious / total events I1: 49 (3.4) / 62 (4.3) C1: 46 (3.2) / 58 (4.0) C2: 26 (1.8) / 41 (2.8) Peripheral vascular disease [no (%)]: serious / total events I1: 7 (0.5) / 36 (2.5) C1: 6 (0.4) / 27 (1.9) C2: 4 (0.3) / 31 (2.2)	see table 'Adverse events'	./.
Ko 2006 I1: rosiglitazone max. 8 mg + (sulfonylurea +/‐ metformin) C1: "bedtime insulin" + (sulfonylurea +/‐ metformin)	not investigated	not investigated	see table 'Adverse events'	./.
Lebovitz 2001 I1: rosiglitazone 4 mg I2: rosiglitazone 8 mg C1: placebo	not investigated	not investigated	see table 'Adverse events'	./.
Ovalle 2004 I1: rosiglitazone 8 mg I2: insulin (premixed 70/30)	not investigated	not investigated	see table 'Adverse events'	./.
Philipps 2001 I1: rosiglitazone 4 mg o.d.; 2 mg b.i.d.; 8 mg o.d.; 4 mg b.i.d. C1: placebo	not investigated	not investigated	see table 'Adverse events'	./.
Raskin 2004 I1: rosiglitazone 8 mg I2: repaglinide 12 mg C1: repaglinide + rosiglitazone 6 / 4 mg	not investigated	not investigated	see table 'Adverse events'	./.
Rosenstock 2006b I1: rosiglitazone 8 mg + metformin 2g + sulfonylurea C1: insulin glargine 10 units/day + metformin 2g + sulfonylurea	not investigated	not investigated	see table 'Adverse events'	./.
Stocker 2007 I1: rosiglitazone 4 mg C1: metformin 1.7 g	not investigated	not investigated	see table 'Adverse events'	./.
Sutton 2002 I1: rosiglitazone 8 mg C1: glyburide (mean 10.5 mg)	not investigated	not investigated	see table 'Adverse events'	./.
Yang 2002 I1: rosiglitazone 4 mg C1: placebo	not investigated	not investigated	see table 'Adverse events'	./.
Footnotes ? = unclear; I = intervention; C = control; o.d. = once daily; b.i.d. = twice daily